ArticleFrontiers in immunology2024
Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recent developments in cancer immuno-interception strategies.Trends in molecular medicine · 2026Review
- Spatially resolved FoxP3 positive lymphocyte infiltration within the tumor microenvironment predicts survival in resected pancreatic ductal adenocarcinoma.Discover oncology · 2026Article
- Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions.Signal transduction and targeted therapy · 2026Review
- Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies.World journal of clinical oncology · 2026Review
- Informed spatially aware patterns for multiplexed immunofluorescence data.Scientific reports · 2026Article
- Targeting the chemokine-Treg axes in tumor immune evasion: from mechanisms to therapeutic opportunities.Frontiers in immunology · 2026Review
- The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer.Biomedicines · 2025Review
- CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies.Frontiers in immunology · 2025Review
- Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospective real-world study.Frontiers in immunology · 2025Article
- Reprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer.Frontiers in immunology · 2025Review
- Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The five-year survival rates for pancreatic ductal adenocarcinoma (PDAC) have scarcely improved over the last half-century. It is inherently resistant to FDA-approved immunotherapies, which have transformed the outlook for patients with other advanced solid tumours. Accumulating evidence relates this resistance to its hallmark immunosuppressive milieu, which instils progressive dysfunction among tumour-infiltrating effector T cells. This milieu is established at the inception of neoplasia by immunosuppressive cellular populations, including regulatory T cells (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.